

017E JC170  
MAY 07 2002  
PATENT & TRADEMARK OFFICE

**CERTIFICATE OF MAILING**

I hereby certify that on 4-29-02, this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231.

Trudi Thompson  
Trudi Thompson

05-16-02  
COPY OF PAPERS  
ORIGINALLY FILED

0400 1617  
PB  
PATENT  
PATENT

Applicant: **Carlyle et al.**  
Serial No.: **10/085,539**  
Filed: **2/26/2002**  
Title: **PEROXISOME PROLIFERATOR-  
ACTIVATED RECEPTOR GAMMA  
LIGAND ELUTING MEDICAL  
DEVICE**

Examiner: **Unassigned**  
Group Art Unit: **1619**  
Atty Docket No.: **17363.35**

**RECEIVED**

MAY 09 2002

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE** FILE CENTER 1600/2900

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. § 1.56, Applicant(s) submit herewith patents, publications, or other information of which they are aware that may be considered in connection with the above-referenced patent application. Submission of this Information Disclosure Statement is not intended to constitute an admission that any patent, publication or other information referred to herein is "material" to Applicants' invention as that term is currently defined in 37 C.F.R. § 1.56 (37 CFR § 1.97(h)).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other relevant information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

A Patent and Trademark Office Form 1449 listing each of these informational items is enclosed along with a copy of each item.

This Information Disclosure Statement is being filed before the mailing date of the first Office Action issued on the merits of the subject application in accordance with

37 C.F.R. §1.97(b)(3). In the event that a first Office Action has been mailed to the undersigned prior to the mailing of this Information Disclosure Statement, the Commissioner is hereby authorized to charge payment of the applicable fee pursuant to 37 C.F.R. § 1.17(p) to Deposit Account No. 50-1901. A duplicate copy of this document is enclosed.

Respectfully submitted,



Louis C. Cullman  
Registration No. 39,645

April 29, 2002

**OPPENHEIMER WOLFF & DONNELLY LLP**  
840 Newport Center Drive, Suite 700  
Newport Beach, CA 92660  
Telephone: 949.823.6000  
Facsimile: 949.823.6100

Please type a plus sign (+) in this box → ☒

MAY 07 2002

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/085539
Filing Date	2/26/2002
First Nam d Inventor	Carlyle
Group Art Unit	1619
Examiner Name	Unknown
Attorney Docket Number	17363.35

Sheet

1

of

1

### U.S. PATENT DOCUMENTS

Examin r Initials	Cite No. <sup>1</sup>	U.S. Patent Document			Date of Publications of Cited Documents MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Wh re Relevant Passages or Relevant Figures Appear
		Number					
		5925657			07/20/1999	Seed et al.	

### FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document			Date of Publications of Cited Documents MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passag s or Relevant Figur s Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup>				

### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Kintscher et al.; Peroxisome Proliferator-Activated Receptor and Retinoid X receptor ligands inhibit Monocyte Chemotactic Protein-1-Directed Migration of Monocytes; European Journal of Pharmacology 401 (2000) 259- 270	
		Reis et al.; Sulindac Inhibits Neointimal Formation After Arterial Injury in Wild-Type and Apolipoprotein E- Deficient Mice; PNAS, November 7, 2000, vol. 97, No. 23, pp. 12764-12769	

COPY OF PAPERS  
ORIGINALLY FILED

RECEIVED  
MAY 09 2002  
TECH CENTER 1600/2900

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent documents. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Order Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, Washington, DC 20231.

OC: 150709 v01 04/27/2002